[New antiplatelet drugs in coronary artery disease].
The dual antiplatelet therapy with acetylsalicylic acid and clopidogrel has been the mainstay of both acute and chronic phase coronary artery disease, reducing importantly the risk of adverse events. Despite a correct compliance, a non-negligible rate of adverse events still happens. New compounds, with improved properties, are now clinically available (such as prasugrel or ticagrelor) or under advanced development. The aim of the present review is the description of these new compounds, particularly prasugrel and ticagrelor.
Servicio de Cardiología, Hospital Clínico Universitario Virgen de la Arrixaca, Universidad de Murcia, El Palmar, Murcia, España. Electronic address: atellomont@hotmail.com.
Antonio
A
Tello-Montoliu
Servicio de Cardiología, Hospital Clínico Universitario Virgen de la Arrixaca, Universidad de Murcia, El Palmar, Murcia, España.
Eva
E
Jover
Servicio de Cardiología, Hospital Clínico Universitario Virgen de la Arrixaca, Universidad de Murcia, El Palmar, Murcia, España.
Mariano
M
Valdés
D000241:Adenosine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D000249:Adenosine Monophosphate / Q000009:adverse effects / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D017326:Clinical Trials, Phase III as Topic; D003324:Coronary Artery Disease / Q000188:drug therapy*; D004311:Double-Blind Method; D004417:Dyspnea / Q000139:chemically induced; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D015337:Multicenter Studies as Topic; D010879:Piperazines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000145:classification / Q000494:pharmacology / Q000627:therapeutic use*; D000068799:Prasugrel Hydrochloride; D016032:Randomized Controlled Trials as Topic; D044462:Receptors, Proteinase-Activated / Q000037:antagonists & inhibitors; D013876:Thiophenes / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D000077486:Ticagrelor; D016896:Treatment Outcome
D010879:Piperazines; D010975:Platelet Aggregation Inhibitors; D044462:Receptors, Proteinase-Activated; D013876:Thiophenes; D000249:Adenosine Monophosphate; C117446:cangrelor; D000068799:Prasugrel Hydrochloride; D000077486:Ticagrelor; D000241:Adenosine
Antiplatelet drugs; Cardiopatía isquémica; Coronary artery disease; Fármacos antiplaquetarios; Intervencionismo coronario percutáneo; Percutaneous coronary interventions